Milestone Pharmaceuticals
MIST
43 hedge funds and large institutions have $9.46M invested in Milestone Pharmaceuticals in 2025 Q1 according to their latest regulatory filings, with 14 funds opening new positions, 6 increasing their positions, 11 reducing their positions, and 17 closing their positions.
332% more call options, than puts
Call options by funds: $311K | Put options by funds: $72K
9% less funds holding
Funds holding: 47 → 43 (-4)
18% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 17
23.88% less ownership
Funds ownership: 46.04% → 22.16% (-24%)
45% less repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 11
84% less capital invested
Capital invested by funds: $57.9M → $9.46M (-$48.5M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBM
Propel Bio Management
Los Angeles,
California
|
+$2.89M |
| 2 |
SAM
Simplify Asset Management
Las Vegas,
Nevada
|
+$1.69M |
| 3 |
LPL Financial
San Diego,
California
|
+$222K |
| 4 |
Walleye Capital
New York
|
+$183K |
| 5 |
Group One Trading
Chicago,
Illinois
|
+$170K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$9.56M |
| 2 |
Millennium Management
New York
|
-$4.73M |
| 3 |
O
OrbiMed
New York
|
-$4.72M |
| 4 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$3.41M |
| 5 |
AFA
Alta Fundamental Advisers
New York
|
-$2.45M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
51
Virtu Financial
New York
| – | -$170K | -71,955 | Closed |
|
52
Envestnet Asset Management
Chicago,
Illinois
| – | -$150K | -63,742 | Closed |
|
53
Squarepoint
New York
| – | -$134K | -56,751 | Closed |
|
|
AI
54
Atria Investments
Charlotte,
North Carolina
| – | -$91.3K | -38,666 | Closed |
|
|
CSS
55
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$73K | -30,938 | Closed |
|
|
BFM
56
Boothbay Fund Management
New York
| – | -$72.7K | -30,790 | Closed |
|
57
Cetera Investment Advisers
Schaumburg,
Illinois
| – | -$58.4K | -24,731 | Closed |
|
|
TSS
58
Two Sigma Securities
New York
| – | -$40K | -16,957 | Closed |
|
59
Osaic Holdings
Scottsdale,
Arizona
| – | -$16.4K | -6,934 | Closed |
|
60
Barclays
London,
United Kingdom
| – | -$236 | -100 | Closed |
|
MIST Hedge Fund Activity: Q1 2025 in Review
43 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Milestone Pharmaceuticals (MIST) for Q1 2025, worth a combined $9.46M — down 84% from $57.9M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of MIST and 14 opened new positions — a net loss of 3 holders — while 11 trimmed existing stakes and 6 added.
The largest buyer was Propel Bio Management, opening a new position worth an estimated $2.89M. The largest seller was BlackRock, exiting entirely with an estimated $9.56M sold.
- 43 institutional investors held Milestone Pharmaceuticals (MIST) as of Q1 2025, down from 47 in Q4 2024.
- Funds reported $9.46M of Milestone Pharmaceuticals stock for Q1 2025, down 84% quarter-over-quarter.
- 14 funds opened new Milestone Pharmaceuticals positions in Q1 2025 and 17 closed out, a net change of -3 holders.
- The largest Milestone Pharmaceuticals buyer in Q1 2025 was Propel Bio Management, an estimated $2.89M added.
- The largest Milestone Pharmaceuticals seller in Q1 2025 was BlackRock, an estimated $9.56M sold.
Based on aggregated 13F filings for Q1 2025.